Synthesis and evaluation of novel pyrazolopyrimidine derivatives as potential anti-cancer agents / (Record no. 176443)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05703namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20251229124957.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 251202s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.19 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.19 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.04.M.Sc.2025.Ah.S |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Ahmed Mahmoud Abdelhamed, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Synthesis and evaluation of novel pyrazolopyrimidine derivatives as potential anti-cancer agents / |
| Statement of responsibility, etc. | by Ahmed Mahmoud Abdelhamed ; Supervision Prof. Dr. Hanan Hassan Kadry, Prof. Dr. Rasha Ahmed Mahmoud Hassan, Prof. Dr. Amira Atef Helwa. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | تشييد وتقييم مشتقات بيرازولو بيريميدين جديدة كعوامل محتملة مضادة للسرطان |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 86 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 79-86. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | This thesis focuses on the design and synthesis of novel pyrazolo[3,4-d]pyrimidine <br/>derivatives of expected anti-cancer activity. It consists of four parts. The first part is a brief <br/>introduction about the synthesis of pyrazolopyrimidine derivatives, their anti-cancer activity. <br/>Followed by an introduction about protein kinases, especially VEGFR-2. In addition to some <br/>examples of pyrazolo[3,4-d]pyrimidine derivatives with anti-cancer activity through VEGFR-2 <br/>inhibition. The second part contains the research objectives which include all the modifications <br/>used to synthesize the new pyrazolo[3,4-d]pyrimidine derivatives using sunitinib as a reference <br/>drug and the schemes adopted for the preparation of target compounds. The third part is a <br/>theoretical discussion of the experimental work for the preparation of pyrazolo[3,4-d]pyrimidines <br/>and a discussion of the biological evaluation of the prepared derivatives as cytotoxic agents and <br/>enzyme assay results of the most potent compound XIIIb. Also, it includes the discussion of <br/>docking studies of the most potent prepared derivatives XIIIa–d against VEGFR-2 using the MOE <br/>program. Finally, the fourth part, explains detailed information about the procedures used for the <br/>synthesis of the target compounds, as well as the physical properties and detailed data obtained <br/>from spectral analysis. Moreover, it includes the methodology followed for the in vitro biological <br/>assays of the synthesized compounds, in addition to the molecular docking steps of the most potent <br/>compounds XIIIa–d. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | تتضمن الرسالة تشييد بعض مركبات البيرازولو]4،3-د [بيرميدين وتقييم تاثيرها كمضاد للسرطان. تنقسم الرسالة اليأربعة أقسام. القسم الأول عبارة عن مقدمة موجزة حول تشييد مشتقات البيرازولو]4،3-د [بيرميدين ونشاطها المضاد للسرطان، تليها مقدمة عنالبروتين كينيز، خاصة مستقبلات عامل النمو البطاني الوعائي-2. (VEGFR-2) بالاضافة الي بعض الامثلة علي مشتقات البيرازولو ]4،3-د[بيرميدين الفعالة كمضاد للسرطانمن خلال تثبيط .VEGFR-2القسم الثاني يشمل الهدف من البحث و الذي يتضمن كل التعديلات المستخدمة لتشييد مشتقات البيرازولو]4،3-د[بيرميدين باستخدام السونيتينيب و السورافينيب كدواء مرجعي مع عرض للمخططات التفصيلية التي توضح الطرق العلمية المختلفة المتبعة للوصول الى المركبات المستهدفة. القسم الثالث يتضمن مناقشة الخطة النظرية للجزء العملي لإعداد المركبات المستهدفة ونتائج الفحوصات الحيوية واختبار الانزيم للمركب الأكثر فاعلية XIIIbونتائجالنمذجة الجزيئية للمركبات الأكثر فاعليةXIIIa–dباستخدام برنامجMOE. اخيرا القسم الرابع يوضح معلومات مفصلة عن الخطوات المستخدمة في تشييد المركبات المستهدفة، بالإضافة إلى الخصائص الفيزيائية وتحاليل العناصر والتحاليل الطيفية للمركبات المشيدة.علاوة على ذلك، يشمل المنهجية المتبعة لإجراء الفحوصات البيولوجية داخل المختبر للمركبات المحضرة، بالإضافة إلى خطوات النمذجة الجزيئية لأكثر المركبات فعالية. XIIIa–d |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutical Chemistry |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | الكيمياء الصيدلية |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Pyrazolo[3,4-d]pyrimidines |
| -- | Synthesis |
| -- | Anti-cancer activity |
| -- | VEGFR-2 |
| -- | Sunitinib |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hanan Hassan Kadry |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rasha Ahmed Mahmoud Hassan |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Amira Atef Helwa |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Hanan Hassan Kadry |
| -- | Rasha Ahmed Mahmoud Hassan |
| -- | Amira Atef Helwa |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmaceutical Organic Chemistry |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 02.12.2025 | 92685 | Cai01.08.04.M.Sc.2025.Ah.S | 01010110092685000 | 02.12.2025 | 02.12.2025 | Thesis |